Lung Neoplasms Clinical Trial
Official title:
Virtual Intervention for Lung Cancer
Lung cancer is the leading cause of cancer death in both men and women. Lung cancer is unique because of racial disparity, persistent mortality rate, and social stigma. Lung cancer stigma (LCS) and difficult patient-clinician communication may be an underlying factor in health disparities in lung cancer. The purpose of this study is to PILOT test, in a diverse sample of lung cancer patients the effectiveness of the mHealth Tool for Lung Cancer patients (mHealthTLC), an interactive, immersive 3-dimensional iPad application that allows individuals to experience first person virtual visits with their clinicians, to improve patient-clinician communication, decrease LCS, and promote optimal self-management. The study hypotheses are that patients who receive the mHealth TLC will improve their ability to communicate effectively with their clinicians and will report decreased stigma related to their lung cancer diagnosis compared to the attention control group.
This is a two arm experimental design PILOT test of the mHealth Tool for Lung Cancer patients
(mHealthTLC) an intervention to improve patient-clinician communication, decrease lung cancer
stigma, and decrease lung cancer symptom scores. Patients will be assigned to either the
mHealth TLC group or the Attention Control Group (ACG). Interventions in both groups will be
delivered online or by iPad in a research office in the clinician's building prior to each
visit. Assessments will be done immediately after each visit in the same research room.
Intervention and assessment pre-visit is expected to take less than one hour, the
intervention is expected to take 30mins, and post assessment is expected to take 30 minutes.
A follow-up assessment will be done at 3 months from enrollment.
mhealth TLC group will meet with a nurse just before each of 4 clinician visits and use the
mHealth TLC on an iPad with an interactive, immersive 3-dimensional (3-D) intervention that
allows individuals to experience virtual visits with their clinicians. The mHealth TLC
provides engagement and experiential learning by delivering important information about
symptom management and provides the opportunity to practice a new communication strategy in
ever increasing complex situations with a virtual coach, receptionist, assistant, and
clinician.During the mHealthTLC the patient will enter a virtual clinic office, travel
through the different aspects of a typical clinic visit, and interact with office staff and
clinicians that are represented by avatars. The avatars will be designed to reflect ethnic
and cultural diversity. First person is the preferred format for health teaching because the
patient is active as self and not represented as an avatar. The first person vantage point
facilitates the immersion and immediacy of the experience. Key aspects of mHealthTLC include
informational videos about lung cancer (i.e. etiology, diagnosis, treatment, symptoms) and
LCS. Blame and self-blame will be addressed, information about the role of addiction,
social/cultural factors, and tobacco industry influence on smoking behaviors will be
highlighted. Information and training will be provided and patients will be able to
experience practiced interaction in ever increasing complex situations with avatars (i.e.,
receptionist, medical assistant, and clinician). A "virtual coach" will accompany the patient
through the virtual visit and will provide information and coaching (as needed). The
advantages to adding a virtual coach or avatar include the availability of an always-live
agent and the capability of customizing the coach to represent an ideal social model for a
particular user or group of users.Flexibility exists in how to design not only how the coach
will appear but also how the coach will sound - with an appropriate voice and engaging
non-verbal communication). This approach contributes to cultural and ethnic sensitivity. As
the patient attempts to communicate and receive information appropriate for a self-management
plan, they will receive "points" for successful communication. A cumulative score and
explanation will be given at the end of the virtual visit. During the visit the participant
will identify specific topics and questions that they want to address during their visit with
their real clinician; they will receive a printout of their priority questions that they can
take into the visit with their real clinician. The research nurse will review the score, the
priority questions, and the overall virtual experience. Virtual environments for learning are
sufficiently promising that further investment and development of this type of research is
warranted.
Attention control group (ACG)- Patients assigned to the ACG will meet with a nurse and
receive the informational videos from the mHealth TLC on an iPad before 4 clinician visits
with assessments after each clinician visit. An effort will be made to match the intervention
condition on salience, credibility, and contact time.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
| Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
| Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
| Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
| Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
| Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|